Effectiveness of electrochemotherapy in treatment of a recurrent squamous cell carcinoma of the scalp.
Electrochemotherapy (ECT) has recently emerged as a treatment for cutaneous and subcutaneous lesions from different malignancies, including squamous cell carcinoma (SCC), with curative or palliative intent [1] . It combines the delivery of electric pulses into the lesions with the effect of anticancer drugs such as bleomycin and cisplatin; the increased cell membrane permeability following the electric pulse enhances drug uptake into tumoral cells and raises the cytotoxicity of these intravenously or intralesionally administered molecules. With respect to surgery, radiotherapy and other standard treatments [2] , ECT acts rapidly on multiple lesions with limited side effects and no functional impairment; moreover, repeated sessions can be performed to achieve or maintain the clinical response.
We present an 80-year-old male admitted at our institution with multiple erythematous nodules, ranging from 0.5 to 1.5 cm in diameter, at the right fronto-parieto-occipital region (figure 1A). One month before he had undergone the excision of an infiltrating squamous cell carcinoma of the vertex; due to its large extension and infiltrating growth a cycle of radiotherapy immediately followed surgery but was interrupted for the appearance of multiple histologically confirmed secondary lesions surrounding the treated area. Due to the number and extension of nodules, standard approaches were excluded; we therefore performed ECT. Treatment was carried out under mild general anaesthesia, with 15 mg/m2 intravenous bleomycin. Electrical pulses were generated and applied using the Cliniporator TM device (IGEA Ltd.) and type III hexagonal electrodes. A response was already observed at week 2 after treatment (figure 1B). At week 8, a relapse of 3 lesions was observed: the recurrences appeared as small necrotic ulcers with erythematous and infiltrated borders, the largest diameter measuring 3.5 cm. Thus, a second ECT was performed and a new complete regression was obtained; at week 4 the infiltration was no longer evident and only residual superficial ulcers covered by necrotic crusts were present. Unfortunately, two months after treatment the patient developed parotid gland and regional lymph node involvement and died 3 months later of a systemic progression.
Since the early 1990s, clinical and preclinical studies have been conducted on ECT, many including cutaneous and mucosal SCC [2, 3] ; but only recently has ECT entered clinical practice and its use in SCC remains limited.
The most recent ECT prospective non-randomized trials [2, 4] included SCC patients: a good clinical activity was reported, with no significant differences in response rates according to nodule size, and without relevant side effects.A recent paper by Landstrom et al. [5] described the results obtained in 6 cases of head and neck skin cancer (HNSC), including 3 SCC: in 4/6 cases, tumour eradication with satisfactory cosmetic results was obtained after only one ECT session, suggesting the alternative role of ECT in complicated skin cancers. In another study including 9 SCC [6] , an 80% CR rate was achieved. The remaining
